The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas

Hepatology. 2016 Feb;63(2):662-4. doi: 10.1002/hep.28307. Epub 2015 Dec 14.

Authors

Lola M Reid^{1

2

3}, Praveen Sethupathy^{3

4}

Affiliations

¹ Department of Cell Biology and Physiology, UNC School of Medicine, Chapel Hill, NC.
² Program in Molecular Biology and Biotechnology, UNC School of Medicine, Chapel Hill, NC.
³ Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC.
⁴ Department of Genetics, UNC School of Medicine, Chapel Hill, NC.

PMID: 26505878
DOI: 10.1002/hep.28307

No abstract available

MeSH terms

Biomarkers, Tumor / genetics*
Carcinoma, Hepatocellular / drug therapy
Carcinoma, Hepatocellular / genetics*
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits / drug effects
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits / genetics*
HSP40 Heat-Shock Proteins / drug effects
HSP40 Heat-Shock Proteins / genetics*
Humans
Liver Neoplasms / drug therapy
Liver Neoplasms / genetics*
Oncogene Proteins, Fusion / drug effects
Oncogene Proteins, Fusion / genetics*

Substances

Biomarkers, Tumor
DNAJB1 protein, human
HSP40 Heat-Shock Proteins
Oncogene Proteins, Fusion
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
PRKACA protein, human

Supplementary concepts

Fibrolamellar hepatocellular carcinoma